Fig. 1.

(A) Results of survey question: “I was aware of the cost increase in LOMUSTINE (GLEOSTINE) prior to this email (check all that apply),” n = 370. In response, 56% answered NO. Of responders who answered YES and were aware, 18% were from media; 15% from patient; and 14% from clinician or staff at their institution; and 7% from colleagues outside their institution. (B) Results of survey question: “Which of the following issues have you personally encountered in prescribing lomustine (GLEOSTINE) to your patients (check all that apply),” n = 213. In response, 64% reported increased staff time in securing insurance approval, 34% insurance denial, 34% patient complaint of increased copay costs, and 36% change in therapy resulting from increased cost.